← Back to Stock Screener← Stock Screener
ZYBERNO
Stock Report
Updated Aug 29, 2026

REPLIGEN CORP (RGEN)

Healthcare • NASDAQ

$176.27
Repligen Corporation is an American life sciences company headquartered in Waltham, Massachusetts, that develops and commercializes bioprocessing components and systems for biopharmaceutical manufacturing. The company's products include Protein A chromatography resins (used to purify monoclonal antibodies), hollow fiber filtration systems, and fluid management products used by biopharmaceutical companies and CDMOs in the production of biologic drugs.

Professional Investment Analysis

ZYBERNO SCORE →
Is it a great business? Is it getting better?
44.0/100
WEAK BUSINESS
REPLIGEN CORP (RGEN) scores 44/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
-100.0%
Overvalued
Is the market underestimating or overestimating what this business is capable of going forward?
-45.3%
Market Overestimates
↑ UNDER
+50%
Brina Gap
-50%
↓ OVER
← OVERVALUED
-100%
Margin of Safety
UNDERVALUED →
+100%
UNDERESTIMATED
GROWTH
DOUBLE
DISCOUNT
EXPENSIVE
HYPE
VALUE
TRAP
0,0
MoS -100.0%  ·  Gap -45.3%

Two independent signals. One tells you if the stock is cheap relative to what the business has historically generated for owners — the Margin of Safety. The other tells you if the market is underestimating what the business is capable of going forward — the Brina Gap.

They are calculated from completely different data sources and answer completely different questions. The Margin of Safety reads the past. The Brina Gap reads the present economics and compares them against what the current stock price is assuming about the future.

When both point in the same direction simultaneously — DOUBLE DISCOUNT — the probability of genuine mispricing is high. The market is wrong on two independent dimensions at once, which is rare and significant.

The most dangerous scenario is not an overvalued stock — those are easy to avoid. It is a VALUE TRAP: a stock that appears cheap historically but where the market is already pricing in stronger growth than the business fundamentals support. Without the Brina Gap signal this looks identical to a genuine opportunity. The matrix separates them instantly.

The Brina Gap is the more powerful of the two signals. Most investors and analytical tools focus on valuation alone — whether a stock is cheap relative to earnings. Far fewer systematically compare what the business economics structurally support against what the stock price is actually assuming. That gap between fundamental growth potential and market expectations is where the most reliable mispricings live, and where this matrix earns its value.

Use this as your first filter. A stock in DOUBLE DISCOUNT territory is worth investigating. Everything else requires either more caution or a specific reason to act.

EXPENSIVE HYPE
In the Brina Matrix, REPLIGEN CORP (RGEN) registers Expensive Hype — Margin of Safety -100.0% and Brina Gap -45.3% are both unfavorable. The stock is priced above its historical earnings power and the market already assumes faster growth than the fundamentals support.
🎯 Expected Annual Return →
-31.2%
Margin of Safety convergence — your return if the market re-prices to intrinsic value (5-yr annualised)
-47.1%
Brina Gap convergence — your return if the market corrects the growth mispricing the Gap measures
1.8%
Yield + growth — what the business alone earns you, even if the market never re-rates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (2.0%)
Debt-to-Equity (Solvency Risk):GOOD (0.32x)
Operating Margin (Operational Efficiency):AVERAGE (8.2%)
Return on Capital (Capital Efficiency):CRITICAL (1.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
💎
Intrinsic Value
DCF Fair Value
$24.80
🛡️
Margin of Safety
Valuation Gap
-100.0%
🎯
Expected Return
Projected Annual
-31.2%
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

According to Zyberno, REPLIGEN CORP (RGEN) is not a buy — WEAK BUSINESS (44/100) with a negative Margin of Safety of -100.0% and a Brina Gap of -45.3% showing the market already prices in more growth than the fundamentals support.

According to Zyberno's DCF model, REPLIGEN CORP (RGEN) trades at $176.27 against an estimated intrinsic value per share of $24.80 — a -100.0% Margin of Safety based on Owner Earnings of $106.04M TTM, projected at 1.8% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -45.3% weakens the case: based on the company's ROIC (1.6%) and reinvestment rate (46.8%), the business can fundamentally grow at 0.7% — but the current enterprise value implies the market expects 46.0%. This places RGEN in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of -31.2% annually.

Over the trailing twelve months, RGEN generated $106.04M in Owner Earnings. Capital was deployed as follows: $88.40K returned via share buybacks, $24.67M invested in capital expenditures. Reinvestment rate: 46.8%. Owner Earnings have grown at 1.8% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:176.27
Market Cap:$9.94B

Valuation Multiples (4)

P/E Ratio:
238.20x
📊 Click to view full RGEN P/E analysis →
P/B Ratio:4.71x
P/S Ratio:12.67x
Peg Ratio:-999.00x

Enterprise Metrics (3)

Enterprise Value:$9.91B
Ev Ebitda Ratio:63.19x
Pfcf Ratio:93.78x

Price Action & Momentum (3)

12-1 Momentum:
+12.7% (53th pctile)
📈 Click to view full RGEN Momentum analysis →
Momentum Percentile:53 / 100
% of 52-Week High:93.4%
B. Profitability Assessment

Return Metrics (7)

ROE:
2.0%
📊 Click to view full RGEN ROE analysis →
ROA:1.4%
Roic:
1.6%
📊 Click to view full RGEN ROIC analysis →
Reinvestment Rate:46.8%
Fundamental Growth Rate (g):0.7%
Market-Implied Growth Rate:46.0%
Brina Gap:
-45.3%
☷ Click to view full RGEN Brina Gap analysis →

Margin Analysis (3)

Operating Margin Ttm:8.2%
Net Margin Ttm:5.3%
Ebitda Margin:20.0%

TTM Performance (3)

Gross Margin Ttm:53.8%
Operating Margin Ttm:8.2%
Net Margin Ttm:5.3%

Yield Metrics (3)

Earnings Yield:$0.42
Owner Earnings Yield:$1.07
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):
-0.16
📊 Click to view full RGEN Earnings Surprise analysis →
EPS Surprise vs Expected:-43.3%
Latest Earnings Filed:2026-07-29

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):3.8%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-30.1%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):7.4%
Operating Cash Flow Growth Rate (Linear):-6.8%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-12.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.05x
Quick Ratio:7.64x
Cash Ratio:4.57x

Leverage Analysis (3)

Debt To Equity Ttm:0.32x
Debt-to-Equity Ratio:0.32x
Debt To Ebitda:3.64x

Coverage Ratios (2)

Interest Coverage Ratio:2.49x
Times Interest Earned:2.49

Capital Structure (4)

Working Capital:1,067,898,000.00
Cash And Cash Equivalents:606,783,000.00
Long Term Debt:$551.05M
Net Debt:-$36.42M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $785.10M
Linear Growth: 3.8%
📊 Click to view full RGEN Revenue analysis & methodology →
Cost Of Revenue Ttm:$362.43M

Profitability Breakdown (2)

Gross profit TTM: $422.67M
Linear Growth: 6.4%
📊 Click to view full RGEN Gross Profit analysis & methodology →
Operating income TTM: $64.61M
Linear Growth: -12.6%
📊 Click to view full RGEN Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: $41.54M
Linear Growth: -30.1%
📊 Click to view full RGEN Net Income analysis & methodology →
Income Before Tax:$52.15M
Ebitda Ttm:156,809,000.00

Operating Expenses (5)

Operating Expenses:720,492,000.00
R And D Expense:56,170,000.00
Sga Expense:301,180,000.00
Income Tax Expense:$10.61M
Interest Expense:22,150,000.00

Expense Ratios (3)

R And D To Revenue Percentage:27.5%
Sga To Revenue Percentage:147.5%
Ebitda Margin:20.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$2.95B
Current Assets:$1.20B
Ppe Net:167,513,000.00
Goodwill:1,104,183,000.00
Intangible Assets:$357.62M

Liability Structure (4)

Total Liabilities:838,148,000.00
Current Liabilities:132,656,000.00
Long Term Debt:$551.05M
Short Term Debt:$19.32M

Equity & Capital (3)

Equity:$2.11B
Retained Earnings:$469.59M
Common Stock:80,000,000.00

Working Capital Items (3)

Accounts Receivable:157,710,000.00
Inventory:186,604,000.00
Accounts Payable:33,233,000.00

Special Items (2)

Contract Liabilities:22,652,000.00
Stock Based Compensation:8,013,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $130.71M
Linear Growth: -6.8%
Free cash flow TTM: $106.04M
Linear Growth: 7.4%
📊 Click to view full RGEN Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$3.99M
Capital Expenditures Ttm:24,666,000.00

Financing Activities (3)

Financing Cash Flow:-$5.54M
Dividends Paid Ttm:0.00
Stock Repurchase:-88,400.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:92,200,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.75
Eps diluted TTM: $0.74
Linear Growth: -29.8%
📊 Click to view full RGEN EPS analysis & methodology →
Earnings Per Share Ttm:$0.74

Revenue & Cash Per Share (3)

Sales Per Share Ttm:13.92
Operating Cash Flow Per Share:$2.08
Fcf Per Share Ttm:1.88

Book Value & Capital (2)

Book Value Per Share:$37.44
Cash Per Share:10.76

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.27x
Working Capital Turnover Ttm:0.74x

Receivables Management (2)

Receivables Turnover Ttm:4.98x
Days Sales Outstanding Ttm:73.32

Inventory Management (2)

Inventory Turnover Ttm:1.94x
Days Inventory Outstanding Ttm:187.93

Payables & Cash Cycle (2)

Days Payable Outstanding:33.47
Cash Conversion Cycle:227.78
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:100.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $106.04M
Linear Growth: 1.8%
📊 Click to view full RGEN Owner Earnings analysis & methodology →
Owner Earnings Per Share:$1.88
Owner Earnings Yield:$1.07

Growth Assessment (1)

Owner Earnings Growth Rate:$1.78

Damodaran Growth Analysis (4)

Reinvestment Rate:46.8%
Fundamental Growth Rate (g):0.7%
Market-Implied Growth Rate:46.0%
Brina Gap:
-45.3%
☷ Click to view full RGEN Brina Gap analysis →

Intrinsic Value Models (1)

Intrinsic Value:
$1.40B
📊 Click to view full RGEN DCF valuation →

Margin of Safety (1)

Margin Of Safety:
-100.0%
📊 Click to view full RGEN valuation analysis →

Return Scenarios (2)

Theoretical 5-Year Return:
-31.2%
📊 Click to view full RGEN expected return analysis →
Forward Expected Return (Yield + Growth):
1.8%
📊 Click to view full RGEN expected return analysis →

Investment Assessment (1)

Buffett Assessment:Overvalued
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (3)

Revenue Growth Rate (Linear):3.8%
Net Income Growth Rate (Linear):-30.1%
Operating Income Growth Rate (Linear):-12.6%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):7.4%
Operating Cash Flow Growth Rate (Linear):-6.8%

Other Growth Rates (3)

Gross Profit Growth Rate (Linear):6.4%
Book Value Growth Rate (Linear):3.8%
Owner Earnings Growth Rate:$1.78
C. Company Profile & Context

Corporate Information (6)

Symbol:RGEN
Company Name:REPLIGEN CORP
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:56.42M
Shares Outstanding Basic:56.42M
Shares Outstanding Diluted:56.64M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-29 20:25:49 UTC
Data Timestamp:2026-08-29T20:25:49.704449
Scroll to Top